BioSphere CE-marks embolisation EmboGold microspheres:
This article was originally published in Clinica
BioSphere Medical has gained the European go-ahead to market its EmboGold microspheres for use in general embolisation procedures, including for uterine fibroid embolisation. The EmboGold microspheres offer advantages over the firm's current flagship product, EmboSphere microspheres, as they are packaged in pre-filled syringes and are tinted to improve visibility. The EmboGold microspheres are also approved in Canada and were launched in the US in September last year.
You may also be interested in...
Siemens Healthineers' product mix of diagnostics and imaging products meant it was in the middle of a very dynamic situation when COVID-19 struck.
The WHO’s new "living guideline" against remdesivir’s use in hospitalized patients notwithstanding, some key opinion leaders in India see a role for the antiviral, but underscore that COVID-19 is still in its infancy and all repurposed therapies for the disease still have a long way to go. They also see the US remdesivir studies as more robust.
Join us for a brief audio tour around the past week's major global biopharma industry developments, in this podcast version of Scrip's Five Must-Know Things.